A Phase 2 interventional study of Memantine Hydrochloride (HCl) and Memantine Hydrochloride (HCl) in Autistic Disorder, Autism and Asperger's Disorder, sponsored by Forest Laboratories. Completed at 94 sites in 15 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-04-24.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.
Among the 603 studies in Autistic Disorder with a site in United States, this one is the 13th largest by enrollment of the 504 interventional ones that give a count, is one of 26 that started in 2012, is one of 95 in phase 2, and was the 187th registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 8–12
Vanderbilt University Medical Center · Sites in United States
Ages 36 mo–72 mo
University of Wisconsin, Madison · Sites in United States
Massachusetts General Hospital · Sites in United States
Ages 7–17
Stony Brook University · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 122 · Phase 3 43 · Phase 4 18
First in 1997; this study’s year is marked. 26 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 479 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 44 across the 504 interventional studies, 135 across the 96 observational. Of the 408 that completed or were terminated, 143 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 603 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AbbVie has 6 studies filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
34 of the studies in Autistic Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02914951Yale UniversityCognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability | 2026-12 |
| NCT06627205Stanford UniversitySleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism | 2026-12 |
| NCT04805957Rutgers, The State University of New JerseyValidation Digital Bio-markers During Sulforaphane Treatment. | 2026-12-01 |
| NCT07421830Northeastern UniversityAn Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism | 2026-12-31 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
Add all 34 to your calendar (.ics) → With an account.
Among the 603 studies in Autistic Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
This clinical study was a 12-week, multicenter, double-blind, placebo-controlled, randomized withdrawal study in pediatric outpatients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). Patients who completed at least 12 weeks of study drug exposure and met protocol specified responder criterion in lead in Study MEM-MD-91 (NCT01592786) at two consecutive visits separated by at least two weeks were eligible to transition to this study. The responder criterion was defined as having at least a 10 point improvement (reduction in score) in the Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 total raw score in Study MEM-MD-91.
Weight based dose limits were selected in this study to ensure that exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng·h/mL which represents a 10-fold lower exposure than observed at the NOAEL(No observed adverse effect level) of 15 mg/kg/day in juvenile rats.
The weight-based dose limits in this study were as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
Drug: Memantine Hydrochloride (HCl)
Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
Drug: Memantine Hydrochloride (HCl)
Dosing will be once daily for up to 12 weeks.
Drug: Placebo capsules
Extended Release Dose ranging from 3-15mg/day; administered orally
Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
Once daily, oral administration.
Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)
Loss of Therapeutic response is defined as a worsening (increase) of at least 10 points in Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 (randomization) score. The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment with total raw score ranging from 0 (no impairment) to 195 (severe social impairment). Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment.
Time frame: Baseline (Visit 1) to week 12
Time to First Loss of Therapeutic (LTR) Response
Time to the first visit when a patient shows LTR following randomization to memantine or placebo.
Time frame: Baseline to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Scripted language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Nonverbal communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
Time frame: Baseline (Visit 1) to week 12
Patient recruitment occurred over a ten month period, from September of 2012 to June of 2013, at 92 study sites, located in the Untied States and 14 other countries.
| Milestone | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Started | 160 | 161 | 158 |
| Completed | 44 | 50 | 50 |
| Not completed | 116 | 111 | 108 |
| Withdrew: Loss of therapeutic response | 107 | 108 | 100 |
| Withdrew: Inclusion/exclusion criteria not met | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Other reasons | 1 | 1 | 0 |
Loss of Therapeutic response is defined as a worsening (increase) of at least 10 points in Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 (randomization) score. The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment with total raw score ranging from 0 (no impairment) to 195 (severe social impairment). Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment.
| Percentage of patients with LTR | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases) | 69.0 | 67.5 | 66.7 |
Time to the first visit when a patient shows LTR following randomization to memantine or placebo.
| Days | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Time to First Loss of Therapeutic (LTR) Response | 29 (28 to 42) | 33 (28 to 56) | 30 (28 to 44) |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12 | 0.1 ± 0.2 | 0.1 ± 0.2 | 0.2 ± 0.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12 | 0.0 ± 0.2 | 0.3 ± 0.2 | 0.1 ± 0.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12 | 0.3 ± 0.2 | 0.7 ± 0.2 | 0.3 ± 0.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12 | 0.7 ± 0.3 | 1.0 ± 0.3 | 1.0 ± 0.3 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12 | 1.4 ± 0.3 | 1.6 ± 0.3 | 1.2 ± 0.3 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Scripted language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12 | 0.8 ± 0.2 | 1.1 ± 0.2 | 0.9 ± 0.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12 | 0.9 ± 0.3 | 0.8 ± 0.3 | 0.8 ± 0.3 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Nonverbal communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12 | 1.2 ± 0.3 | 1.5 ± 0.3 | 1.8 ± 0.3 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12 | 1.5 ± 0.3 | 1.8 ± 0.3 | 1.8 ± 0.3 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times \[more than twice\] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).
| units on a scale | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12 | 0.9 ± 0.3 | 1.3 ± 0.3 | 1.2 ± 0.3 |
Collected over Adverse events were collected for a 14 month period from September of 2012 to October of 2013 at 92 study centers in the United States and 14 other countries.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/160 (0%) | 8/160 (5%) |
| Memantine Reduced Dose | — | 1/160 (0.6%) | 5/160 (3.1%) |
| Memantine Full-Dose | — | 0/157 (0%) | 4/157 (2.5%) |
| Event | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| FuruncleInfections and infestations | 0/160 | 1/160 | 0/157 |
| Event | Placebo | Memantine Reduced Dose | Memantine Full-Dose |
|---|---|---|---|
| IrritabilityGeneral disorders | 8/160 | 5/160 | 4/157 |
479 patients were screened and randomized. Of these, 477 patients received at least 1 dose of double-blind investigational product (Safety Population). The baseline characteristics presented here are for the Safety population.
| Age, Continuous(years) | Placebo | Memantine Reduced Dose | Memantine Full-Dose | Total |
|---|---|---|---|---|
| Mean | 8.9 ± 2.0 | 9.2 ± 1.9 | 9.2 ± 1.9 | 9.1 ± 1.9 |
| Sex: Female, Male(Participants) | Placebo | Memantine Reduced Dose | Memantine Full-Dose | Total |
|---|---|---|---|---|
| Female | 18 | 28 | 25 | 71 |
| Male | 142 | 132 | 132 | 406 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Memantine Reduced Dose | Memantine Full-Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 22 | 15 | 60 |
| Not Hispanic or Latino | 137 | 138 | 142 | 417 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Memantine Reduced Dose | Memantine Full-Dose | Total |
|---|---|---|---|---|
| White | 138 | 141 | 140 | 419 |
| Black or African American | 10 | 9 | 7 | 26 |
| Asian | 7 | 5 | 8 | 20 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Other | 4 | 3 | 2 | 9 |
| Region of Enrollment(Participants) | Placebo | Memantine Reduced Dose | Memantine Full-Dose | Total |
|---|---|---|---|---|
| United States | 134 | 125 | 126 | 385 |
| Belgium | 2 | 1 | 1 | 4 |
| Colombia | 1 | 2 | 2 | 5 |
| Estonia | 0 | 1 | 0 | 1 |
| France | 1 | 4 | 2 | 7 |
| Hungary | 3 | 3 | 2 | 8 |
| Iceland | 0 | 3 | 0 | 3 |
| Italy | 2 | 1 | 1 | 4 |
| Korea, Republic of | 6 | 3 | 5 | 14 |
| New Zealand | 0 | 1 | 1 | 2 |
| Poland | 5 | 6 | 10 | 21 |
| Serbia | 3 | 6 | 5 | 14 |
| South Africa | 0 | 0 | 1 | 1 |
| Spain | 1 | 0 | 1 | 2 |
| Ukraine | 2 | 4 | 0 | 6 |
| Autism Spectrum Disorder Subtype(Participants) | Placebo | Memantine Reduced Dose | Memantine Full-Dose | Total |
|---|---|---|---|---|
| Autism | 101 | 99 | 100 | 300 |
| Asperger's Disorder | 30 | 30 | 27 | 87 |
| PDD-NOS | 29 | 31 | 30 | 90 |
The record gives a start of Sep 2012, a primary completion of Sep 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine